Altheia Science
A gene therapy company.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
* | N/A | €8.0m | Series A |
| Total Funding | 000k | ||
| EUR | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | - | - | (13 %) | (60 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | - | - | (51 %) | (59 %) | (358 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Altheia Science, founded in 2017, is a biotechnology company developing cell and gene therapies for autoimmune diseases and cancer. The company was founded by two distinguished Italian scientists, Prof. Alessandra Biffi, MD, and Prof. Paolo Fiorina, MD, PhD, in collaboration with the investment firm AurorA-TT. The leadership team includes CEO and co-founder Dr. Paolo Rizzardi, who brings a blend of scientific and managerial expertise to the company.
The company's primary focus is on creating curative treatments for autoimmune disorders by targeting the underlying causes of the disease. Altheia Science engineers hematopoietic stem cells to modulate the immune system, aiming to provide long-term solutions for patients. This approach is also being explored for applications in oncology.
Altheia Science operates from its headquarters in Milan, Italy, and has a US office in New York. The company has secured $19.3 million in funding to advance its research and development efforts. Its business model revolves around the discovery, development, and eventual commercialization of its therapeutic products, targeting a market with significant unmet medical needs.
Keywords: cell therapy, gene therapy, autoimmune diseases, biotechnology, oncology, hematopoietic stem cells, immunology, pharmaceuticals, life sciences, medical research